Gene Therapy Working Group

The Gene Therapy Working Group is a permanent working group of the SECB. It supports the SECB in its advisory tasks concerning the authorization of clinical trials of gene therapy or with genetically modified organisms (GMOs) as well as market authorizations of such products.

Members of the Gene Therapy Working Group (external experts)


  • Pedro Romero, Prof. em. MD, Deputy scientific managing director Ludwig Institute for Cancer Research, Lausanne


  • Pascal Meylan, Prof. em. MD, University Hospital Center (CHUV), Lausanne


  • Carlo V. Catapano, MD, PhD, Oncology Institute of Southern Switzerland, Bellinzona
  • Angela Ciuffi, Prof. PhD, Lausanne University Hospital Center and University of Lausanne (CHUV-UNIL)
  • Hussein Naim, PhD, Life Sciences and Vaccines Consultant, Bern
  • Sandro Rusconi, Prof. em. PhD, Repubblica e Cantone Ticino, Divisione della Cultura e degli Studi Universitari, Bellinzona

Executive Office

  • Elisabetta Peduzzi, PhD, Executive Manager SECB, Bern

To the top

Last edition: 14.06.2022